Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer (ESMO) Basic Listing

Updates in Non-Small Cell Lung Cancer
From the ESMO Congress

David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
APP Institute Oncology
Conference Coverage
Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
09/25/2024
Stephanie Holland
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to exploratory results...
09/25/2024
Oncology
Nicolas Girard, MD
Videos
Adding Relatlimab to First-Line Nivolumab and Chemotherapy Demonstrates Clinical Benefit in Advanced Non-Small Cell Lung Cancer
09/14/2024
Nicolas Girard, MD
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
Nicolas Girard, MD, PhD,...
09/14/2024
Oncology
Conference Coverage
Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer
09/10/2024
Allison Casey
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
According to exploratory...
09/10/2024
Oncology
Conference Coverage
Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer
09/10/2024
Stephanie Holland
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the...
09/10/2024
Oncology
Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
Stephanie Holland
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology

Recent News

Conference Coverage
Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
09/25/2024
Stephanie Holland
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to exploratory results...
09/25/2024
Oncology
Conference Coverage
Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer
09/10/2024
Allison Casey
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
According to exploratory...
09/10/2024
Oncology
Conference Coverage
Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer
09/10/2024
Stephanie Holland
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the...
09/10/2024
Oncology
Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
Stephanie Holland
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use